ENTITY
Brii Biosciences

Brii Biosciences (2137 HK)

36
Analysis
Health Care • China
Brii Biosciences is a biotechnology company focused on developing therapies for infectious and central nervous system diseases. The company has a broad pipeline of therapeutic candidates, with lead programs targeting hepatitis B virus (HBV) infection, and also develops treatments for multi-drug resistant bacterial infections. Brii Biosciences is headquartered in Beijing, China, and was founded in 2017.
more
•15 Jul 2021 12:13

Kindstar (康圣环球) IPO Trading: Pattern of Demand Divergence

We look at the updates on Kindstar IPO since our last note. With its valuation higher than leading ICL peer, we do not expect a strong debut...

Logo
480 Views
Share
•12 Jul 2021 12:52

Brii Biosciences (腾盛博药) IPO Trading: Note the Pre-IPO Investors Subscription

We look at the updates since our last note for Brii. We note that the allocation to institutional investors were heavily concentrated in the...

Logo
507 Views
Share
•04 Jul 2021 10:21

ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•30 Jun 2021 12:48

Brii Biosciences (腾盛博药) IPO: Not a Demanding Valuation for Its Differentiation

We provide an update for the book building of Brii IPO. We think the valuation of the deal is not demanding with upside for investors.

Logo
601 Views
Share
•28 Jun 2021 10:11

Brii Biosciences (腾盛博药) Pre-IPO: Thoughts on Valuation

We provide our thoughts on the pre-money valuation for Brii Biosciences. We valued the BRII-179/BRII-835 for HBV and BRII-778/BRII-732 for HIV...

Logo
591 Views
Share
x